TREK-1 isoforms generated by alternative translation initiation display different susceptibility to the antidepressant fluoxetine

Neuropharmacology

Volumn 61, Issue 5-6, 2011, Pages 918-923

  Eckert, Michaela ^a   Egenberger, Brigitte ^a   Döring, Frank ^a   Wischmeyer, Erhard ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Antidepressants; ATI isoforms; Background current; Cellular excitability; K 2P channels; SSRI

Indexed keywords

FLUOXETINE; MAPROTILINE; TANDEM PORE DOMAIN POTASSIUM CHANNEL; TASK 1 PROTEIN; THIK 1 PROTEIN; TREK 1 PROTEIN; UNCLASSIFIED DRUG; VENLAFAXINE;

AMINO ACID COMPOSITION; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CHANNEL GATING; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; XENOPUS;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DNA; FLUOXETINE; GENETIC VECTORS; HEK293 CELLS; HUMANS; MEMBRANE PROTEINS; MYOCYTES, CARDIAC; NERVE TISSUE PROTEINS; NEURONS; OOCYTES; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS, TANDEM PORE DOMAIN; PROTEIN BIOSYNTHESIS; PROTEIN ISOFORMS; SENSITIVITY AND SPECIFICITY; SEROTONIN UPTAKE INHIBITORS; TRANSFECTION; XENOPUS LAEVIS;

EID: 80051796941     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.06.020     Document Type: Article

References (30)

1. J.S. Choi, S.J. Hahn, D.J. Rhie, S.H. Yoon, Y.H. Jo, and M.S. Kim Mechanism of fluoxetine block of cloned voltage-activatedpotassium channel Kv1.3 J. Pharmacol. Exp. Ther. 291 1999 1 6 (Pubitemid 29451565)
2. L.N. Cornelisse, J.E. Van der Harst, J.C. Lodder, P.J.J. Baarendse, A.J. Timmermann, H.D. Mansvelder, B.M. Sprujit, and A.B. Brussaard Reduced 5-HT1a and GABAb receptor function in dorsal raphé neurons upon chronic fluoxetine treatment in socially stressed rats J. Neurophysiol. 98 2007 196 204 (Pubitemid 47084811)
3. F. Duprat, F. Lesage, M. Fink, R. Reyes, C. Heurteux, and M. Lazdunski TASK, a human background K+ channel to sense external pH EMBO J. 16 1997 5464 5471
4. + channel EMBO J. 15 1996 6854 6862
5. C. Heurteaux, G. Lucas, N. Guy, M.E. Yacoubi, S. Thümmler, X. Peng, F. Noble, N. Blondeasu, C. Widmann, M. Borsotto, G. Gobbi, J.-M. Vaugeois, G. Debonnel, and M. Lazdunski Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype Nat. Neurosci. 9 2006 1134 1141 (Pubitemid 44306306)
6. E.M. Johnson, E. Whyte, B.H. Mulsant, G.B. Pollock, E. Weber, and A.E. Begley Cardiovascular changes associated with venlafaxine in the treatment of late-life depression Am. J. Geriatr. Psychiatry 14 2006 796 802 (Pubitemid 44380072)
7. L.E. Kennard, J.R. Chumbley, K.M. Ranatunga, S.J. Armstrong, E.L. Veale, and A. Mathie Inhibition of the human two-pore domain potassium channel TREK-1 by fluoxetine and its metabolite norfluoxetine Br. J. Pharmacol. 144 2005 821 829 (Pubitemid 40516121)
8. I. Lauritzen, N. Blondeau, C. Heurteaux, C. Widmann, G. Romey, and M. Lazdunski Polyunsaturated fatty acids are potent neuroprotectors EMBO J. 19 2000 1784 1793 (Pubitemid 30204390)
9. Y.J. Liou, T.J. Chen, S.J. Tsai, W.Y. Yu, C.Y. Cheng, and C.J. Hong Support for the involvement of the KCNK2 gene in major depressive disorder and response to antidepressant treatment Pharmacogenet. Genomics 19 2009 735 741
10. + channel EMBO J. 19 2000 2483 2491 (Pubitemid 30323538)
11. + channels TREK-1 and TRAAK J. Biol. Chem. 275 2000 10128 10133 (Pubitemid 30202065)
12. A. Mathie, and E.L. Veale Therapeutic potential of neuronal two-pore domain potassium channel modulators Curr. Opin. Investig. Drugs 8 7 2007 555 562 (Pubitemid 47016323)
13. C. Martinez, T.L. Assimes, D. Mines, S. Dell'Aniello, and S. Suissa Use of venlafaxine with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study BMJ 340 2010 10.1136/bmj.c249
14. Y. Maruyama, and M. Yamada TREK-1: a novel target for antidepressants Nihon Shinkei Seishin Yakurigaku Zasshi 27 2007 147 151
15. J. Mazella, O. Pétrault, G. Lucas, E. Deval, S. Béraud-Dufour, C. Gandin, M. El-Yacoubi, C. Widmann, A. Guyon, E. Chevet, S. Taouji, G. Conductier, A. Corinus, T. Coppola, G. Gobbi, J.H. Nahon, C. Heurteaux, and M. Borsotto Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design PLoS Biol. 8 4 2010 e1000355
16. + channels TREK-1 and TRAAK Brain Res. 892 2001 94 101 (Pubitemid 32126571)
17. P. Pacher, J. Magyar, P. Szigligeti, T. Bányász, C. Pankucsi, Z. Korom, Z. Ungvári, V. Kecskeméti, and P.P. Nánási Electrophysiological effects of fluoxetine in mammalian cardiac tissues Naunyn Schmiedebergs Arch. Pharmacol. 361 1 2000 67 73 (Pubitemid 30064656)
18. 2+ and transient outward K+ currents in rat ventricular myocytes Yonsei Med. J. 40 2 1999 144 151
19. + channel EMBO J. 17 1998 4283 4290 (Pubitemid 28362619)
20. + channels Nat. Neurosci. 2 1999 422 426 (Pubitemid 30491251)
21. R.H. Perlis, P. Moorjani, J. Fagerness, S. Purcell, M.H. Trivedi, M. Fava, A.J. Rush, and J.W. Smoller Phamacogenetic analysis of genes implicated in models of antidepressant response: association of TREK1 and treatment resistance in the STARD study Neuropsychopharamcol 33 2008 2810 2819
22. C. Putzke, K. Wemhöner, F.B. Sachse, S. Rinne, G. Schlichthörl, X.T. Li, L. Jae, I. Eckhard, E. Wischmeyer, H. Wulf, R. Preisig-Müller, J. Daut, and N. Decher The acid-sensitive potassium channel TASK-1 in rat cardiac muscle Cardiovasc. Res. 75 1 2007 59 68 (Pubitemid 46873507)
23. G. Sandoz, S.C. Bell, and E.Y. Isacoff Optical probing of a dynamic membrane interaction that regulates the TREK-1channel Proc. Natl. Acad. Sci. U S A 108 2011 2605 2610
24. D. Simkin, E.J. Cavanough, and D. Kim Control of the single channel conductance of K2P10.1 (TREK-2) by the amino-terminus: role of alternative translation initiation J. Physiol. (Lond.) 586 2008 5651 5663
25. E.M. Talley, and D.A. Bayliss Modulation of TASK-1 (Kcnk3) and TASK-3 (Kcnk9) potassium channels J. Biol. Chem. 277 2002 17733 17742
26. D. Taylor Venlafaxine and cardiovascular toxicity BMJ 340 2010 327
27. D. Thomas, L.D. Plant, C.M. Wilkens, Z.A. McCrossan, and S.A.N. Goldstein Alternative translation initiation in rat brain yields K2P2.1 potassium channels permeable to sodium Neuron 58 2008 859 870 (Pubitemid 351842748)
28. D. Thomas, B. Gut, G. Wendt-Nordahl, and J. Kiehn The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go related gene (HERG) potassium channels J. Pharmacol. Exp. Ther. 300 2002 543 548
29. S. Thümmler, F. Duprat, and M. Lazdunski Antipsychotics inhibit TREK but not TRAAK channels Biophys. Biochem. Res. Comm. 354 2007 284 289 (Pubitemid 46137960)
30. S.J. Tsai Sipratigine could have therapeutic potential for major depression and bipolar depression through antagonism of the two-pore-domain K+ channel TREK-1 Med. Hypotheses 70 3 2008 548 550